XML 47 R23.htm IDEA: XBRL DOCUMENT
v3.21.1

Revenues and Other Income | 12 Months Ended
--- | ---
Dec. 31, 2020
Revenues and Other Income |
Revenues and Other Income | Note 17. Revenues and Other Income
|  | Year ended
|  | December 31,
(in thousands of euros) |  | 2018 |  | 2019 |  | 2020
Sales |  | 3,197 |  | 6,998 |  | 372
Total revenues |  | 3,197 |  | 6,998 |  | 372
CIR |  | 4,166 |  | 4,293 |  | 4,791
Subsidies |  | 16 |  | — |  | —
Other |  | — |  | 0 |  | 100
Total other income |  | 4,182 |  | 4,293 |  | 4,891
Total revenues and other income |  | 7,379 |  | 11,291 |  | 5,263
Revenues In 2020, revenue amounted to €0.4 million. The decrease in revenue compared to 2019 is mainly explained by (i) no milestone payment triggered according to the collaboration agreement with AbbVie and (ii) the termination of the collaboration agreement with BI in the fourth quarter of 2019. In 2019, revenue amounted to €7.0 million and primarily included:
| · |  | the €3.5 million milestone payment from AbbVie received in December 2019 following the enrollment of the first patient with psoriasis in the ongoing clinical trial of ABBV-157;
| · |  | the reversal of all contract liabilities recognized at December 31, 2018 following the termination of all contracts with BI. The reversal amounted to €2.2 million, including €2.1 million following termination of the BI Collaboration in the fourth quarter of 2019 (see Notes 15, “Contract liabilities”).
In 2019, revenue from research partnerships with Abbvie and BI represented 51.4% and 36.9% of the Company's revenue, respectively. In 2018, revenue was primarily composed of fees received from AbbVie, BI and, to a lesser extent, other parties in return for research services rendered by the Company, no milestone payment having been received in 2018. In 2018, revenue was primarily composed of fees received from AbbVie, BI and, to a lesser extent, other parties in return for research services rendered by the Company, no milestone payment having been received in 2018. CIR In 2018, 2019 and 2020, the CIR corresponds only to the amount of research tax credit recorded for each period: €4.1 million for 2018, €4.3 million for 2019 and €4.8 million for 2020.

X
- Definition The entire disclosure for revenue. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfRevenueExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | iva_RevenueAndOtherIncomeAbstract
Namespace Prefix: | iva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration